Abstracts tagged "interstitial lung disease"

Abstract Number: 369 • 2019 ACR/ARP Annual Meeting
Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review
Esteban Rubio¹, Alejandro Muñoz ¹ and Núria Casamira ², ¹Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, ²Medical Department, Gebro Pharma S.A., Barcelona, Spain
Background/Purpose: Methotrexate (MTX) is a commonly used drug for inflammatory joint diseases. Occasionally, its use has been associated with diffuse interstitial lung disease (DILD) development1. A…
Abstract Number: 1636 • 2019 ACR/ARP Annual Meeting
Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial
Maureen Mayes¹, Kristin Highland ², Martina Gahlemann ³, Aryeh Fischer ⁴, Ganesh Raghu ⁵, Mannaig Girard ⁶, Margarida Alves ⁷, Susanne Stowasser ⁷, Jörg Distler ⁸, Marco Matucci-Cerinic ⁹, Elizabeth Volkmann ¹⁰, Masataka Kuwana ¹¹ and Oliver Distler ¹², ¹Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁴University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ⁵University of Washington, Seattle, USA, Seattle, ⁶Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁹University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, ¹⁰University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ¹¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ¹²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: The presence of anti-topoisomerase I antibody (ATA) in patients with systemic sclerosis (SSc) has been associated with a greater risk of developing interstitial lung…
Abstract Number: 2339 • 2019 ACR/ARP Annual Meeting
Exposure to Avian and Fungal Antigens in Patients with Rheumatoid Arthritis-AssociatedInterstitial Lung Disease: Something to Keep in Mind
Sebastian Rodriguez-Garcia¹, Raul Castellanos-Moreira ², Fernanda Hernández-González ³, Albert Perez ⁴, Joel Francesqui ⁵, Sandra Cuerpo-Cardeñosa ⁵, Virginia Ruiz-Esquide ⁶, Mariana Benegas ⁷, José Ramírez ⁸, Carmen Lucena-Pozo ³, Carlos Agustí ³, Marc Boada ⁹, Estíbaliz Ruiz ⁴, Odette Viñas ⁴, Sergio Prieto-González ¹⁰, Raimon Sanmarti ¹¹, Gerard Espinosa ¹², Mariona Pascal ¹³, Jose Gomez-Puerta ¹¹, Marcelo Sánchez ⁷ and Jacobo Sellares ³, ¹Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, ²Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ³Department of Pneumology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁴Department of Immunology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁵Pneumology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁶Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁷Department of Radiodiagnosis, Hospital Clínic, Barcelona, Barcelona, Spain, ⁸Department of Pathological Anatomy, Hospital Clínic, Barcelona, Barcelona, Spain, ⁹Department of Thoracic Surgery, Hospital Clínic, Barcelona, Barcelona, Spain, ¹⁰Department of Systemic Autoimmune Diseases Hospital Clínic, Barcelona, Barcelona, Spain, ¹¹Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ¹²Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ¹³Immunology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain
Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is an extra-articular manifestation with a poor prognosis. In clinical practice, to establish such a diagnosis requires…
Abstract Number: 370 • 2019 ACR/ARP Annual Meeting
Use of Serum Lung Injury Biomarkers for Predicting the Severity of Interstitial Lung Disease in Patients with Connective Tissue Disease Associated Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features
Sogol Amjadi¹, Tracy Frech ², Jessica Chan ³, Mary Beth Scholand ⁴, Troy Jaskowski ⁵, Sonia La’ulu ⁵, Jonathan Genzen ⁶, Dorota Lebiedz-Odrobina ⁷ and Ann Tebo ⁶, ¹University of Utah, Department of Internal Medicine, Division of Rheumatology, West Jordan, UT, ²Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ³University of Utah, Department of Radiology, salt lake city, UT, ⁴University of Utah, Department of Internal Medicine, Division of Pulmonary Medicine, salt lake city, UT, ⁵ARUP Institute for Clinical and Experimental Pathology, salt lake city, UT, ⁶ARUP Institute for Clinical and Experimental Pathology , University of Utah, Department of Pathology, salt lake city, UT, ⁷University of Utah, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: Fibrotic lung diseases encompass a wide spectrum of clinical entities including connective tissue disease related interstitial lung disease (CTD-ILD) and interstitial pneumonia with autoimmune…
Abstract Number: 1643 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use
Madelon Vonk¹, Oliver Distler ², Daniel Furst ³, Eric Hachulla ⁴, Sindhu Johnson ⁵, Shervin Assassi ⁶, Leslie Meng ⁷, Manuel Quaresma ⁸, Margarida Alves ⁸, Emmanuelle Clerisme-Beaty ⁸ and Wim Wuyts ⁹, ¹Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³University of California, Los Angeles, CA, ⁴Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, ⁵Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada, Toronto, Canada, ⁶Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁹Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC)…
Abstract Number: 2340 • 2019 ACR/ARP Annual Meeting
Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis
Takeshi Shoda¹, Tohru Takeuchi ², Takuya Kotani ², Koji Nagai ², Kennichiro Hata ², Shigeki Makino ² and Shigeki Arawaka ², ¹Yodogawa christian hospital / Osaka medical college, Osaka, Japan, ²Osaka medical college, Osaka, Japan
Background/Purpose: Interstitial lung disease (ILD) complicated with rheumatoid arthritis (RA) is detected in 27 to 67% of patients on high-resolution computed tomography (HRCT), and airway…
Abstract Number: 374 • 2019 ACR/ARP Annual Meeting
The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
Eric Matteson¹, Clive Kelly ², Jörg Distler ³, Anna Maria Hoffmann-Vold ⁴, James Seibold ⁵, Shikha Mittoo ⁶, Oliver Distler ⁷, Rainer-Georg Goeldner ⁸, Rozsa Schlenker-Herceg ⁹, Susanne Stowasser ¹⁰, Manuel Quaresma ¹⁰ and Kevin Flaherty ¹¹, ¹Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, ²Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, Newcastle, United Kingdom, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁵Scleroderma Research Consultants LLC, Aiken, South Carolina, USA, Aiken, ⁶University Health Network, Toronto, Ontario, Canada, Toronto, Canada, ⁷Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ⁸Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, ¹⁰Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹¹University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: Some patients with autoimmune disease develop progressive fibrosing interstitial lung disease (ILD) characterized by increasing fibrosis on HRCT, decline in lung function, worsening symptoms…
Abstract Number: 1644 • 2019 ACR/ARP Annual Meeting
Effects of Nintedanib in Patients with Diffuse and Limited Cutaneous Systemic Sclerosis and Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial
Masataka Kuwana¹, Kristin Highland ², Martina Gahlemann ³, Christopher Denton ⁴, Aryeh Fischer ⁵, Maureen Mayes ⁶, Virginia Steen ⁷, Dinesh Khanna ⁸, Yannick Allanore ⁹, Mannaig Girard ¹⁰, Margarida Alves ¹¹, Susanne Stowasser ¹¹ and Oliver Distler ¹², ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁴University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ⁵University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ⁶Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁷Georgetown University, Washington, D.C., USA, Georgetown, ⁸Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁹Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ¹⁰Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ¹¹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Patients with diffuse cutaneous systemic sclerosis (dcSSc) are at greater risk of developing interstitial lung disease (ILD) than patients with limited cutaneous systemic sclerosis…
Abstract Number: 2341 • 2019 ACR/ARP Annual Meeting
Findings of Pulmonary Abnormalities on High Resolution Computed Tomography in a Cohort of Rheumatoid Arthritis Patients Without Known Lung Disease
Scott Matson¹, Kevin Deane ², Christopher Collora ¹, Xi Zheng ¹, Marie Fester ¹, Joyce Lee ¹ and M. Kristen Demoruelle ³, ¹University of Colorado, Denver, ²University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora
Background/Purpose: Pulmonary manifestations of rheumatoid arthritis (RA) lead to significant morbidity and mortality. Lung manifestations in RA are myriad, however little is known about how…
Abstract Number: 385 • 2019 ACR/ARP Annual Meeting
Distinctive Clinical Features and Biomarkers of Connective Tissue Disease Associated Interstitial Lung Disease
Sang Wan Chung¹, So-Yun Lee ¹, Sang-Hoon Lee ¹, Seung-Jae Hong ¹ and Yeon-Ah Lee ¹, ¹School of Medicine, Kyung Hee University, seoul, Republic of Korea
Background/Purpose: The connective tissue diseases (CTD) are a group of rheumatologic diseases characterized by inflammation and immune-mediated organ damage including interstitial lung disease (ILD). The…
Abstract Number: 1648 • 2019 ACR/ARP Annual Meeting
Systemic Sclerosis Auto-antibody Profiles Predict Interstitial Lung Disease Onset but Not Progression
Boyang Zheng¹, Mianbo Wang ², Marvin Fritzler ³, May Choi ³, Murray Baron ⁴ and Marie Hudson ⁵, ¹Jewish General Hospital, McGill University, Montreal, QC, Canada, ²Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Jewish General Hospital, McGill University, Montreal, Canada, ⁵Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is frequent manifestation and a leading cause of mortality in systemic sclerosis (SSc). Some SSc-related autoantibodies (aAbs), especially anti-topoisomerase I…
Abstract Number: 2342 • 2019 ACR/ARP Annual Meeting
Association of Serum KL-6 Level and Change of Pulmonary Function in Interstitial Lung Disease of Rheumatoid Arthritis – Data from Prospective KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) Study
Jeong Seok Lee¹, Young Im Yoon ², Eun Young Lee ³, Jung Yoon Choe ⁴, Hwa Jung Lee ⁵, Yong-Beom Park ⁶, Eun Ha Kang ⁷, You-Jung Ha ⁷, Yeon-Ah Lee ⁸ and Seong Hye Jang ⁹, ¹Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, ²Seoul National University Hospital, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea, ⁴Division of Rheumatology, Daegu Catholic University Medical Center, Daegu, Republic of Korea, ⁵DAEGU CATHOLIC UNIVERSITY, Daegu, Republic of Korea, ⁶Yonsei university college of medicine, severance hospital, Seodaemun-gu, Seoul-t'ukpyolsi, Republic of Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ⁸School of Medicine, Kyung Hee University, Seoul, Republic of Korea, ⁹Soonchunhyang University, Cheonan, Republic of Korea
Background/Purpose: Interstitial lung disease (ILD) is the most common lung disease among rheumatoid arthritis (RA) patients. Although the overall mortality rates for RA have decreased…
Abstract Number: 708 • 2019 ACR/ARP Annual Meeting
Improvement and Stabilization of Lung Function in Patients with SSc-ILD Treated with Nintedanib vs Placebo in a Randomized, Placebo-Controlled Phase III Trial: Proportions of Patients with FVC Changes Using Cutoffs Previously Proposed to Define Minimally Clinically Important Differences
Yannick Allanore¹, Dinesh Khanna ², Elizabeth Volkmann ³, Christian Stock ⁴, Martina Gahlemann ⁵, Nils Schoof ⁶, Oliver Distler ⁷ and Toby Maher ⁸, ¹Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ²Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ⁴Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁵Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁷Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ⁸National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom
Background/Purpose: Mean change in forced vital capacity percent predicted (FVC %pred) is a common endpoint in the assessment of treatment-related outcomes in patients with interstitial…
Abstract Number: 1649 • 2019 ACR/ARP Annual Meeting
Mycophenolate Mofetil and Cyclophosphamide Improve Health-Related Quality of Life in Patients with Systemic Sclerosis Who Participated in SLS II
Elizabeth Volkmann¹, Donald Tashkin ², Michael Roth ³, Holly LeClair ², Philip Clements ², Daniel Furst ⁴, Robert Elashoff ² and Dinesh Khanna ⁵, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴University of California, Los Angeles, CA, ⁵Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc). The majority of studies investigating novel therapies for…
Abstract Number: 2344 • 2019 ACR/ARP Annual Meeting
Efficacy of Mycophenolate Mofetil in the Treatment of Rheumatoid Arthritis Associated Interstitial Lung Disease
Jonathan Amos¹, Jennifer Kendall ¹, Robyn Moran ², Megan Krause ³, Paul Schmidt ⁴, Chase Hall ⁵, Mark Hamblin ⁶ and Mehrdad Maz ⁷, ¹University of Kansas Medical Center, Division of Rheumatology, KANSAS CITY, KS, ²University of Kansas Medical Center, Kansas City, KS, ³University of Kansas, KANSAS CITY, KS, ⁴University of Kansas Medical Center, Division of Rheumatology, Kansas City, ⁵University of Kansas Medical Center, Division of Pulmonary and Critical Care, KANSAS CITY, ⁶University of Kansas Medical Center, Division of Pulmonary and Critical Care, Kansas City, KS, ⁷The University of Kansas Medical Center, KANSAS CITY, KS
Background/Purpose: Interstitial lung disease (ILD) as an extra-articular manifestation of rheumatoid arthritis (RA) leads to significant morbidity and mortality. As data is limited, this study…